Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with the combination of entinostat, nivolumab, and ipilimumab

Ludmila Danilova; Joseph A. Tandurella; Edgar Gonzalez; A. G. Hopkins; Jesse Kreger; Judy Murray; Melinda Downs; Aaron Baugh; Batul Al-zubeidy; Luciane Tsukamoto Kagohara; Adam L. MacLean; Vered Stearns; Roisín M. Connolly; Elana J. Fertig; Evanthia T. Roussos Torres

doi:10.1038/s43856-026-01908-9

Enriched recordOpen access

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with the combination of entinostat, nivolumab, and ipilimumab

Ludmila Danilova, Joseph A. Tandurella, Edgar Gonzalez, A. G. Hopkins, Jesse Kreger, Judy Murray, Melinda Downs, Aaron Baugh, Batul Al-zubeidy, Luciane Tsukamoto Kagohara, Adam L. MacLean, Vered Stearns, Roisín M. Connolly, Elana J. Fertig, Evanthia T. Roussos Torres

Communications Medicine2026doi:10.1038/s43856-026-01908-9

Citation graph

Abstract

No public abstract is available from the verified source records.